Rhamnose-analogues mediated liposomal drug delivery system for pancreatic cancer target therapy
10.16438/j.0513-4870.2023-1344
- VernacularTitle:鼠李糖类似物介导的脂质体递药系统及其靶向抗胰腺癌的研究
- Author:
Fei-yan GAO
1
;
Xin-long LIU
1
;
Shan PENG
1
;
Yan ZHANG
2
;
Chong LI
1
Author Information
1. College of Pharmaceutical Sciences, Southwest University, Chongqing 400715, China
2. School of Pharmacy, Chongqing University, Chongqing 401331, China
- Publication Type:Research Article
- Keywords:
rhamnolipid;
polyphyllin VII;
targeted drug delivery system;
pancreatic cancer
- From:
Acta Pharmaceutica Sinica
2024;59(4):1067-1078
- CountryChina
- Language:Chinese
-
Abstract:
In this study, we have firstly investigated the feasibility of rhamnolipids as targeting ligands to develop drug delivery systems for active targeting of pancreatic cancer. Rhamnolipid-modified liposomes (RhaL-Lip) were prepared by a thin film hydration method, and were evaluated preliminarily for RhaL-Lip physicochemical properties, in vitro release characteristics, ex/in vivo targeting, and in vitro pharmacodynamics. RhaL-Lip exhibited excellent targeting ability of human pancreatic cancer (BxPC-3) cells and enhanced anti-tumor effects. On this basis, the natural structural analogue of rhamnolipid, Polyphyllin VII (PPVII), as the targeting material and active ingredient, we explored the targeting and anti-tumor activity of Polyphyllin VII modified liposomes (PPVII-Lip). The results showed that PPVII-Lip has a homogeneous particle size and has a more robust targeting ability for solid tumor in vivo, which can achieve more enrichment at the tumor site. Compared with gemcitabine, the first-line chemotherapy drug for pancreatic cancer, PPVII-Lip showed a stronger inhibitory effect. In conclusion, this targeted drug delivery strategy is expected to provide beneficial ideas for drug delivery studies in targeted therapy for pancreatic cancer. Animal experiments were conducted with approval from the Animal Ethics Committee of southwest university (approval number: IACUC-20210130-2).
